The Life Sciences team represented Arrakis Therapeutics, a pioneering biopharmaceutical company, in the completion of its $38 million Series A financing led by Canaan Partners with participation by Advent Life Sciences, Pfizer Inc., Celgene Corporation, Osage University Partners and biotech industry leader Henri Termeer. The company has named serial entrepreneur and biotech leader Michael Gilman, Ph.D., as chairman and chief executive officer.
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company’s TRYST™ and PEARL-seq™ platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today’s medicines. Arrakis is developing a proprietary pipeline of RNA-targeted small molecules focused on neurologic diseases, cancer and rare genetic diseases.
The team was led by partner Kingsley Taft and associates Nathan Needle and Coleen Doyle.
For additional details on the transaction, please read the press release.